4.4 Article

Biospecimen Reporting for Improved Study Quality (BRISQ)

期刊

CANCER CYTOPATHOLOGY
卷 119, 期 2, 页码 92-101

出版社

WILEY
DOI: 10.1002/cncy.20147

关键词

BRISQ; best practices; biobank; biospecimen; human; quality; research; guidelines

资金

  1. National Cancer Institute, National Institutes of Health [HHSN261200800001E]

向作者/读者索取更多资源

Human biospecimens are subjected to collection, processing, and storage that can significantly alter their molecular composition and consistency. These biospecimen preanalytical factors, in turn, influence experimental outcomes and the ability to reproduce scientific results. Currently, the extent and type of information specific to the biospecimen preanalytical conditions reported in scientific publications and regulatory submissions varies widely. To improve the quality of research that uses human tissues, it is crucial that information on the handling of biospecimens be reported in a thorough, accurate, and standardized manner. The Biospecimen Reporting for Improved Study Quality (BRISQ) recommendations outlined herein are intended to apply to any study in which human biospecimens are used. The purpose of reporting these details is to supply others, from researchers to regulators, with more consistent and standardized information to better evaluate, interpret, compare, and reproduce the experimental results. The BRISQ guidelines are proposed as an important and timely resource tool to strengthen communication and publications on biospecimen-related research and to help reassure patient contributors and the advocacy community that their contributions are valued and respected. Cancer (Cancer Cytopathol) 2011;119:92-101. Published 2011 by the American Cancer Society.*

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Viral strategies for circumventing p53: the case of severe acute respiratory syndrome coronavirus

Camila Martin Cardozo, Pierre Hainaut

Summary: Most viruses have evolved strategies to evade p53, a key cellular defense mechanism. Different viruses use hit and run, hide and seek, kidnap and exploit, or dominate and suppress tactics against p53. SARS-CoV targets p53 for degradation, potentially impacting Covid-19 pathogenesis and cancer risk.

CURRENT OPINION IN ONCOLOGY (2021)

Article Cell Biology

Finding the Value in Biobanks: Enhancing the CTRNet Locator

Lise A. Matzke, Tamsin E. Tarling, Brent Gali, Simon Dee, Jodi LeBlanc, Suzanne Vercauteren, Peter H. Watson

Summary: Biobanks are essential for research infrastructure, but sustaining them in their current form may be challenging. This article discusses the drivers of biobank value, emphasizing research utilization and impact as key measures of future value.

BIOPRESERVATION AND BIOBANKING (2022)

Article Cell Biology

Analysis of Trends in Biospecimen Complexity in Cancer Research Over Two Decades

Lauren Wotton, Brent Gali, Karlene Carvalho, Tamsin Tarling, Lise Matzke, Peter H. Watson

Summary: Researchers' demand for biospecimens has increased over time, leading to changes in the complexity and collection pathways of biospecimens used in cancer research. Biobanks need to adjust their operational models to support the supply of these types of biospecimens for sustainability and to meet changing research demands.

BIOPRESERVATION AND BIOBANKING (2022)

Article Cell Biology

What Do Biomedical Researchers Want from Biobanks? Results of an Online Survey

Amanda Rush, Daniel R. Catchpoole, Georget Reaiche-Miller, Thomas Gilbert, Wayne Ng, Peter Hamilton Watson, Jennifer A. Byrne

Summary: The survey revealed that most researchers were satisfied with the biobank application processes and the suitability of received biospecimens/data, but they still preferred creating their own collections due to gaps in sample availability and to increase efficiency. Researchers mostly accessed biobanks in close proximity to them, and they often had to limit the scope of their research due to difficulties in obtaining biospecimens/data.

BIOPRESERVATION AND BIOBANKING (2022)

Article Cell Biology

How Many Health Research Biobanks Are There?

Sheila O'Donoghue, Simon Dee, Jennifer A. Byrne, Peter Hamilton Watson

Summary: It is important to know the number of biobanks that exist, but this information is often hard to find. The study analyzed four biobank locators and found that there are 11-30 health research biobanks per million population in regions with high research capacity. The establishment of biobank locators can help track the number of biobanks and prevent duplication of resources.

BIOPRESERVATION AND BIOBANKING (2022)

Article Oncology

Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores

Alexandre Perrier, Pierre Hainaut, Pierre-Jean Lamy, Alexandre Guenoun, Dinh-Phong Nguyen, Fabrice Guerber, Frederic Troalen, Jerome Alexandre Denis, Mathieu Boissan

Summary: The concept of tumor markers has undergone profound changes with the development of high-throughput sequencing technology. Traditional tumor markers are still valuable for prognosis evaluation, treatment selection and optimization, as well as treatment effectiveness monitoring.

BULLETIN DU CANCER (2022)

Article Biochemistry & Molecular Biology

The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute

Kelvin Cesar de Andrade, Elaine E. Lee, Elise M. Tookmanian, Chimene A. Kesserwan, James J. Manfredi, Jessica N. Hatton, Jennifer K. Loukissas, Jiri Zavadil, Lei Zhou, Magali Olivier, Megan N. Frone, Owais Shahzada, William J. R. Longabaugh, Christian P. Kratz, David Malkin, Pierre Hainaut, Sharon A. Savage

CELL DEATH AND DIFFERENTIATION (2022)

Letter Oncology

Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry

Judith Penkert, Farina J. Struewe, Christina M. Dutzmann, Beate B. Doergeloh, Emilie Montellier, Claire Freycon, Myriam Keymling, Heinz-Peter Schlemmer, Birte Saenger, Beatrice Hoffmann, Tanja Gerasimov, Claudia Blattmann, Sebastian Fetscher, Michael Fruhwald, Simone Hettmer, Uwe Kordes, Vita Ridola, Sabine Kroiss Benninger, Angela Mastronuzzi, Sarah Schott, Juliane Nees, Aram Prokop, Antje Redlich, Markus G. Seidel, Stefanie Zimmermann, Kristian W. Pajtler, Stefan M. Pfister, Pierre Hainaut, Christian P. Kratz

Summary: Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by pathogenic TP53 variants, with high risk of developing cancer. The study found that the occurrence of NULL variants were significantly higher in LFS families compared to attenuated LFS families, and there are genotype-phenotype correlations in different types of pathogenic variants and cancer types.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Article Oncology

The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer

Sepideh Soukhtehzari, Richard B. Berish, Ladan Fazli, Peter H. Watson, Karla C. Williams

Summary: This study provides the first detailed report of polySia and CD56 in breast cancer, demonstrating their prognostic significance depending on the cell type expression within the tumor.

NPJ BREAST CANCER (2022)

Article Oncology

Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer

Christian P. Kratz, Dmitrii Smirnov, Robert Autry, Natalie Jaeger, Sebastian M. Waszak, Anika Grosshennig, Riccardo Berutti, Mareike Wendorff, Pierre Hainaut, Stefan M. Pfister, Holger Prokisch, Tim Ripperger, David Malkin

Summary: This study investigated the role of BRCA1, BRCA2, and mismatch repair genes in the risk of childhood and adolescent cancer. The results showed significant associations between pathogenic variants in these genes and the occurrence of certain tumors, but not with hematologic neoplasms. These findings provide new evidence for predictive genetic testing and surveillance.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Editorial Material Genetics & Heredity

Biobanking and research quality: think locally, act globally

Amanda Rush, Peter Watson, Jennifer A. Byrne

Summary: Although biobanks can support research across boundaries, researchers prefer collaborating with local biobanks or establishing their own. This article summarizes the potential impacts of local biobank use and suggests improving descriptions of bio-specimen provenance in research publications.

TRENDS IN GENETICS (2023)

Review Medicine, Research & Experimental

The Availability of Human Biospecimens to Support Biomarker Research

Tamsin E. Tarling, Jennifer A. Byrne, Peter H. Watson

Summary: Preserved biospecimens in biobanks and clinical archives are important for biomarker research. However, recent advancements in technology have led to an excess supply of biospecimens, prompting a need to reassess inventory targets and allocate resources more effectively.

BIOMARKER INSIGHTS (2022)

Article Oncology

Moving towards a personalized oncology: The contribution of genomic techniques and artificial intelligence in the use of circulating tumor biomarkers

Alexandre Perrier, Pierre Hainaut, Alexandre Guenoun, Dinh-Phong Nguyen, Pierre-Jean Lamy, Fabrice Guerber, Frederic Troalen, Jerome Alexandre Denis, Mathieu Boissan

Summary: Technological advancements, particularly high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. Liquid biopsies, which involve the detection of circulating tumor cells and/or circulating tumor DNA in blood samples, provide a genetic snapshot of the patient's tumor and facilitate real-time monitoring of the disease. These new approaches require the processing of large amounts of clinical data and the use of artificial intelligence, but also raise ethical concerns and implications for the healthcare system.

BULLETIN DU CANCER (2022)

暂无数据